ICER to Consider Aetion RWE in Revision of Hereditary Angioedema Therapy Report
ICER (the Institute for Clinical and Economic Review) has announced its decision to utilize RWE (real world evidence) data in [...]
Remdesivir FDA Decision Alert Added to Aetion’s RWE Library
Aetion’s FDA Decision Alert Library includes examples of FDA submissions using RWE (real world evidence) and RWD (real world data). [...]
Webinar on RWE’s Role in Accelerating Drug Development
A webinar is now available featuring discussions with Drs. Nicolle Gatto, Senior Vice President of Scientific Research at Aetion; Julie [...]
RWD in Action: Determining COVID-19 Reinfection Odds
RWD (real world data) is critical in understanding the likelihood of COVID-19 reinfection. One recent study sought to identify the [...]
Aetion’s Take on RWE Expansion in Europe
Aetion’s Ashley Jaska, Vice President of Science, and Nicholas Deltour, Vice President of Real-World Solutions, offered their insight into how [...]
Conversation with Aetion Chief Legal and Executive Officer Provides Insight
Lowell Schiller, J.D., now the Chief Legal and Executive Officer at Aetion, discussed his views on RWE, the FDA, and [...]
Read Up On How Regulators Are Using RWE
RWE is playing a growing role in FDA approvals. According to an Aetion analysis, 49 percent of submissions for new drugs [...]
Real World Evidence Poised to Tip the Balance in Fight Against COVID-19 Through Aetion’s Series B Platform
Tech startup Aetion has added US$19 million to their real-world evidence platform Series B, bringing their round to US$82 million. [...]
Aetion analyzes RWE impact in 4 recent FDA decisions in infectious disease
Senior Directors from Aetion (Purpura and Harvey) analyzed four approvals for products intended to treat or prevent infectious diseases from [...]
Aetion, Cegedim Partnership Looks to Bring Together RWD, Clinical Trial Tech
A new partnership between Aetion and Cegedim Health Data looks to integrate real-world data compiled from European sources into clinical [...]
RCTs vs. RWE? Why Not Both?
Aetion Co-Founder and President Jeremy Rassen in a recent blog post discusses a new paradigm in which randomized controlled trials [...]
COTA’s Narayanan Talks RWD in Interview with Aetion
COTA Healthcare's Life Sciences Vice President Viraj Narayanan in a recent interview with Aetion discussed how oncological real-world data can [...]
Aetion, HealthVerity Launch RWE System
Aetion and HealthVerity last month launched a new real-world evidence system aimed at helping the assessment of treatment approaches for [...]
Article Highlights FDA Decisions that Involved RWE
A recent article published on Aetion looks at three recent decisions by the Food and Drug Administration (FDA) that included [...]
Aetion Launches FDA Decision Alerts
Aetion announced the launch of a new library of FDA submissions that used real-world data and real-world evidence, the FDA [...]
Aetion, HealthVerity Launch New Tools for Assessing COVID-19 Treatments
Aetion and HealthVerity have launched a new set of tools for biopharma companies and regulators looking to assess new COVID-19 [...]
ICER Announces RWE Partnership with Aetion
The Institute for Clinical and Economic Review (ICER) is partnering with Aetion to "generate decision-grade real-world evidence," the drug pricing [...]
